证券代码：300937 证券简称：药易购 公告编号：2024-036 四川合纵药易购医药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）依据中华人民共和 国财政部（以下简称"财政部"）发布的相关企业会计准则解释及规定要求变更 会计政策。根据《深圳证券交易所创业板股票上市规则》有关规定，本次会计政 策变更无需提交公司董事会及股东大会审议，现将具体情况公告如下： 一、会计政策变更情况概述 （一）变更原因 1、2023 年 8 月 1 日，财政部发布了《关于印发<企业数据资源相关会计处 理暂行规定>的通知》（财会〔2023〕11 号）（以下简称"《暂行规定》"）， 规定"企业数据资源相关会计处理"的内容，自 2024 年 1 月 1 日起施行。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将执 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan for the first half of 2024, representing a year-over-year growth of 15%[4]. - The company's operating revenue for the first half of 2024 was CNY 2,225,319,754.46, representing a 0.93% increase compared to CNY 2,204,845,065.75 in the same period last year[15]. - In the first half of 2024, the company's revenue reached 2.225 billion yuan, a year-on-year increase of 0.93%, while net profit attributable to shareholders was 12.0957 million yuan, a decline of 74.11%[22]. - The company's net profit attributable to shareholders decreased by 74.11% to CNY 12,095,746.45 from CNY 46,717,668.57 in the previous year[15]. - The total comprehensive income for the first half of 2024 was CNY 23,372,979.02, down from CNY 51,287,749.46 in the first half of 2023, representing a decrease of approximately 54.4%[142]. - The company's net profit for the first half of 2024 was ¥8,831,979.09, down from ¥56,989,412.01 in the previous year, marking a decrease of around 84.5%[138]. - The company's basic and diluted earnings per share fell by 73.47% to CNY 0.13 from CNY 0.49 in the previous year[15]. - The company reported a significant decline in non-recurring profit and loss, with a net profit of CNY 8,481,216.66, down 80.80% from CNY 44,163,173.51 in the previous year[15]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the same period last year[4]. - The company is expanding its market presence, targeting an increase in the number of retail locations by 25% over the next year[4]. - The company has established partnerships with over 1,800 pharmaceutical manufacturers, holding more than 12,000 pharmaceutical product distribution qualifications[24]. - The company aims to enhance its C-end reach and develop a new industrial model to improve pricing power and create a series of high-quality pharmaceutical products[22]. - The company is focusing on risk control in emerging business development, managing costs, and improving funding management during the cultivation period of the second growth curve[22]. Strategic Initiatives - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 15%[4]. - New product launches are expected to contribute an additional 200 million yuan in revenue by the end of 2024[4]. - The company plans to pursue strategic acquisitions to bolster its market position, with a budget of 500 million yuan allocated for potential deals[4]. - The company is actively investing in internet pharmaceutical retail projects, including the establishment of a B2C e-commerce operation base in Hangzhou[28]. - The company is exploring potential mergers and acquisitions to strengthen its market position[151]. Financial Management and Investments - Investment in new technology development has increased by 30%, focusing on enhancing supply chain efficiency[4]. - The company has established a credit system for small and micro customers, granting credit to 1,534 customers with a total credit amount of 25.53 million yuan during the reporting period[30]. - The company has set up a private equity fund to accelerate resource integration and investment opportunities in the pharmaceutical industry[29]. - The company has recognized data resources as intangible assets on the balance sheet, with a book value of 1,939,429.99 yuan as of the end of the reporting period[30]. - The company reported a total of 3,271.65 million CNY in related party transactions during the reporting period, with a maximum approved transaction amount of 19,320 million CNY[103]. Operational Challenges - The company has identified key risks, including intensified market competition and regulatory changes, which may impact future performance[3]. - The company's gross profit margin has decreased, influenced by a decline in retail scale in the pharmaceutical terminal market and a high comparable base from the previous year due to a public health event[22]. - The B2B e-commerce platform has seen a decrease in monthly active customers, leading to a decline in revenue, affected by regulatory requirements for unified management of retail chain headquarters[22]. - The company faces intensified market competition and changing demand, necessitating increased investment in promotions and R&D, which may not yield expected results[78]. Cash Flow and Financial Position - The net cash flow from operating activities improved significantly, reaching CNY 3,376,800.31, compared to a negative CNY 87,880,002.16 in the same period last year, marking a 103.84% increase[15]. - The company's cash and cash equivalents decreased by 72.43% to -¥55,734,803.18, mainly due to accelerated customer collections and improved inventory turnover[50]. - The total cash inflow from operating activities was CNY 1,714,242,712.44 in the first half of 2024, down from CNY 2,064,085,285.80 in the first half of 2023, representing a decrease of approximately 16.9%[143]. - The company reported a cash outflow of ¥1.45 billion for purchasing goods and services in the first half of 2024, compared to ¥1.89 billion in the previous year, reflecting a decrease of approximately 23.1%[145]. Corporate Governance and Compliance - The company has established a comprehensive management system and enhanced its internal processes to support long-term strategic development[43]. - The company emphasizes strict compliance with e-commerce laws and consumer protection regulations to mitigate risks in information security and business ethics[42]. - The company has maintained a commitment to transparency and accurate information disclosure, ensuring that shareholders are informed of significant matters[90]. - The financial report was approved by the board on August 27, 2024, ensuring compliance with accounting standards[160]. Research and Development - The company aims to enhance its research and development capabilities to drive future growth[151]. - Research and development investment decreased by 10.13% to ¥11,033,371.43, primarily due to reduced MAH R&D expenditures[50]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and product offerings[180]. - The company is focusing on research and development of new products to strengthen its market position[159].

证券代码：300937 证券简称：药易购 公告编号：2024-034 四川合纵药易购医药股份有限公司 关于公司收到民事判决书暨诉讼进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 公司近日收到广州市黄埔区人民法院出具的《民事判决书》（（2022）粤 0112 民初 33048 号），判决如下： 1、案件所处的诉讼阶段：一审判决； 2、公司所处的当事人地位：被告、反诉原告； 3、涉案的金额：判决金额人民币 4,400 万元及相关费用； 4、对公司损益产生的影响：本次判决为一审判决，最终诉讼、执行结果及 对公司本期及期后利润的影响存在不确定性，敬请投资者注意投资风险。 一、本次诉讼事项的基本情况 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2022 年 11 月 10 日收到广东省广州市黄埔区人民法院送达的《民事起诉状》《应诉通知书》等 法律文书，原告杨亚、曹继军以公司为被告提起民事诉讼，具体内容详见公司在 巨潮资讯网（www.cninfo.com.cn）披露的《关于公司收到民事起诉状的公告》（公 告编号：2022-072）。 原 ...

证券代码：300937 证券简称：药易购 公告编号：2024-033 四川合纵药易购医药股份有限公司 关于签署《关于设立及收购目标公司之合作框架协议》的 进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn ...

Group 1: Company Overview - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. is actively exploring new industrial models, focusing on MAH, OEM, and CRO sectors to enhance its pharmaceutical ecosystem [2] - The company has established subsidiaries such as Jinpeifang and Hezhong Zehui to support its pharmaceutical licensing and development efforts [3] - The company aims to optimize its product structure and improve gross profit margins by increasing the number and quality of held licenses and product specifications [3] Group 2: Sales and Marketing Strategy - The company is exploring offline retail as a traffic entry point, aiming to diversify its service offerings and develop chronic disease management services [3] - An "AI Membership" retail model is being promoted to enhance sales while maintaining the integrity of the pharmaceutical supply chain [3] - The company is transitioning its sales model from treating diseases to preventive health, focusing on a broader range of health products [3] Group 3: Competitive Advantage and Future Direction - The core competitive advantages include innovative internet and big data technologies, a comprehensive pharmaceutical service ecosystem, and extensive upstream channel resources [4] - The company has built a C-end operational team and system to leverage its core competencies and cultivate a second growth curve [4] - The first growth curve has provided the company with leading technical strength and infrastructure capabilities, which are essential for its future development [4]

证券代码：300937 证券简称：药易购 公告编号：2024-032 四川合纵药易购医药股份有限公司 关于签署《关于设立及收购目标公司之合作框架协议》的 进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn ...

四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn） 披露的《关于签署<关于设立及收购目标公司之合作框架协议>的提示性公告》（公 告编号：2021-041）。 前期，目标公司已完成设立并取得了营业执照，公司已依约向共管账户支付 诚意金 5,000 万元，基于诚信原则并按照前期协议约定允许将诚意金用于商品采 购及 ...

证券代码：300937 证券简称：药易购 公告编号：2024-030 四川合纵药易购医药股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司(以下简称"公司")2023 年年度权益分 派方案已获 2024 年 4 月 30 日召开的 2023 年度股东大会审议通过，具体详见公 司于 2024 年 4 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露的《2023 年度 股东大会决议公告》。现将权益分派事宜公告如下： 一、股东大会审议通过的利润分配方案的情况 1、公司 2023 年度具体利润分配方案为：以目前总股本 95,666,682 股为基 数，每 10 股派发现金红利 2.20 元人民币（含税），共计派发现金股利人民币 21,046,670.04 元（含税），剩余未分配利润继续留存公司用于支持公司经营需 要，不送红股，不实施以资本公积金转增股本。如在利润分配预案披露至实施期 间，公司总股本发生变动的，公司拟维持每股分配比例不变的原则，相应调整分 配总数。 2、本次权益分 ...

公司以原告及目标公司为反诉被告向法院提出了反诉，诉讼请求为：（1） 判令解除反诉原告与反诉被告一杨亚、反诉被告二曹继军签订的《合作意向书》、 《关于设立及收购目标公司之合作框架协议》、《合作框架协议之补充协议》。 （2）判令反诉被告一、二立即为反诉被告三办理更名及工商变更登记手续，反 诉被告三不再使用"药易购"作为其企业名称组成部分。（3）判令三反诉被告 共同向反诉原告双倍返还诚意金 1 亿元，并自 2023 年 5 月 17 日起以 1 亿元为基 数，按全国银行间同业拆借中心公布的一年期贷款市场报价利率支付逾期付款利 息，直至三反诉被告全部付清之日止。（4）判令三反诉被告共同向反诉原告赔 偿审计费、评估费、公证费、律师费、差旅费等各项损失，并依法承担本案诉讼 费、保全费、担保费。 进展公告 证券代码：300937 证券简称：药易购 公告编号：2024-029 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设 ...

出席本次说明会的人员有：公司董事长李燕飞女士；副董事长、总经理陈顺 军先生；董事会秘书沈金洋先生；财务总监郑德强先生；保荐代表人罗泽先生； 独立董事邓博夫先生等。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录深 圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）的"云访谈"栏目 进入公司本次业绩说明会页面进行提问。公司将在 2023 年度业绩说明会上，对 投资者普遍关注的问题进行回答。此次活动交流期间，投资者仍可登陆活动界面 进行互动提问。 欢迎广大投资者积极参与本次网上说明会！ 特此公告。 四川合纵药易购医药股份有限公司 证券代码：300937 证券简称：药易购 公告编号：2024-028 四川合纵药易购医药股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）《2023 年年度报告》 及摘要已于 2024 年 4 月 10 日在巨 ...